Metnase mediates chromosome decatenation in acute leukemia cells

Blood

Volumn 114, Issue 9, 2009, Pages 1852-1858

  Wray, Justin ^a   Williamson, Elizabeth A ^a   Sheema, Sheema ^a   Lee, Suk Hee ^b   Libby, Edward ^a   Willman, Cheryl L ^c   Nickoloff, Jac A ^d,e   Hromas, Robert ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); METNASE; NUCLEASE; UNCLASSIFIED DRUG; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; ETOPOSIDE; HISTONE LYSINE METHYLTRANSFERASE; SETMAR PROTEIN, HUMAN; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANAPHASE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMATID; CHROMOSOME; CONTROLLED STUDY; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; APOPTOSIS; BIOLOGICAL MODEL; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOSIS; PHYSIOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES; DNA; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOSIS; MODELS, BIOLOGICAL;

EID: 70349263952     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175760     Document Type: Article

References (35)

1. Nickoloff JA, De Haro LP, Wray J, Hromas R. Mechanisms of leukemia translocations. Curr Opin Hematol. 2008;15:338-345.
2. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM, Johnson RT. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature. 1994;372:467-470. (Pubitemid 24365454)
3. Clarke DJ, Vas AC, Andrews CA, Diaz-Martinez LA, Gimenez-Abian JF. Topoisomerase II checkpoints: universal mechanisms that regulate mitosis. Cell Cycle. 2006;5:1925-1928.
4. Toyoda Y, Yanagida M. Coordinated requirements of human topo II and cohesin for metaphase centromere alignment under Mad2-dependent spindle checkpoint surveillance. Mol Biol Cell. 2006;17:2287-2302. (Pubitemid 44011744)
5. Mikhailov A, Shinohara M, Rieder CL. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol. 2004;166:517-526. (Pubitemid 39097171)
6. Skoufias DA, Lacroix FB, Andreassen PR, Wilson L, Margolis RL. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol Cell. 2004;15:977-990. (Pubitemid 39277993)
7. Damelin M, Bestor TH. The decatenation checkpoint. Br J Cancer. 2007;96:201-205.
8. Deming PB, Cistulli CA, Zhao H, et al. The human decatenation checkpoint. Proc Natl Acad Sci U S A. 2001;98:12044-12049.
9. Doherty SC, McKeown SR, McKelvey-Martin V, et al. Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst. 2003;95:1859-1868. (Pubitemid 38054686)
10. Nakagawa T, Hayashita Y, Maeno K, et al. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines. Cancer Res. 2004;64:4826-4832. (Pubitemid 38924526)
11. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3:430-440. (Pubitemid 34685700)
12. Lee SH, Oshige M, Durant ST, et al. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A. 2005;102:18075-18080. (Pubitemid 41798504)
13. Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, Lee SH. Human Pso4 is a Metnase (SETMAR)-binding partner that regulates Metnase function in DNA repair. J Biol Chem. 2008;283:9023-9030.
14. Hromas R, Wray J, Lee SH, et al. The human set and transposase domain protein Metnase interacts with DNA ligase IV and enhances the efficiency and accuracy of non-homologous endjoining. DNA Repair (Amst). 2008;7:1927-1937.
15. Plasterk RH, Izsvak Z, Ivics Z. Resident aliens: the Tc1/mariner superfamily of transposable elements. Trends Genet. 1999;15:326-332. (Pubitemid 29343731)
16. Roman Y, Oshige M, Lee YJ, et al. Biochemical characterization of a SET and transposase fusion protein, Metnase: its DNA binding and DNA cleavage activity. Biochemistry. 2007;46:11369-11376. (Pubitemid 47556764)
17. Miskey C, Papp B, Mates L, et al. The ancient mariner sails again: transposition of the human Hsmar1 element by a reconstructed transposase and activities of the SETMAR protein on transposon ends. Mol Cell Biol. 2007;27:4589-4600. (Pubitemid 46906579)
18. Liu D, Bischerour J, Siddique A, Buisine N, Bigot Y, Chalmers R. The human SETMAR protein preserves most of the activities of the ancestral Hsmar1 transposase. Mol Cell Biol. 2007;27:1125-1132. (Pubitemid 46174572)
19. Cordaux R, Udit S, Batzer MA, Feschotte C. Birth of a chimeric primate gene by capture of the transposase gene from a mobile element. Proc Natl Acad Sci U S A. 2006;103:8101-8106. (Pubitemid 43801059)
20. Williamson EA, Rasila KK, Corwin LK, et al. The SET and transposase domain protein Metnase enhances chromosome decatenation: regulation by automethylation. Nucleic Acids Res. 2008;36:5822-5831.
21. O'Rourke JP, Ness SA. Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol Cell Biol. 2008;28:2091-2101.
22. Williamson EA, Farrington J, Martinez L, et al. Expression levels of the human DNA repair protein metnase influence lentiviral genomic integration. Biochimie. 2008;90:1422-1426.
23. Westendorf JM, Rao PN, Gerace L. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci U S A. 1994;91:714-718. (Pubitemid 24041472)
24. Xu D, Yoder M, Sutton J, Hromas R. Forced expression of Genesis, a winged helix transcriptional repressor isolated from embryonic stem cells, blocks granulocytic differentiation of 32D myeloid cells. Leukemia. 1998;12:207-212. (Pubitemid 28108073)
25. Bishop JF. Approaches to induction therapy with adult acute myeloid leukaemia. Acta Haematol. 1998;99:133-137. (Pubitemid 28154558)
26. Dingemans AM, Pinedo HM, Giaccone G. Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta. 1998;1400:275-288.
27. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411-424. (Pubitemid 37238869)
28. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13:1859-1876.
29. O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 2007;27:1267-1272.
30. Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol. 2007;83:733-741. (Pubitemid 350219111)
31. Valkov NI, Sullivan DM. Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat. 2003;6:27-39. (Pubitemid 36396112)
32. Hansen LT, Lundin C, Helleday T, et al. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer. 2003;40:157-164. (Pubitemid 36438716)
33. Toner GC, Frydenberg M. Poor prognosis germ-cell tumors: an unresolved challenge. Semin Urol Oncol. 2002;20:251-261. (Pubitemid 35463057)
34. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta. 1998;1400:173-184. (Pubitemid 28475102)
35. Joel S. The clinical pharmacology of etoposide: an update. Cancer Treat Rev. 1996;22:179-221.